VASO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VASO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vaso has the GF Score of 44, which implies that the company might have Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
1. Financial Strength : 8/10Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Vaso might have Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Health Information Services subindustry, Vaso's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Vaso's GF Score distribution charts can be found below:
* The bar in red indicates where Vaso's GF Score falls into.
Vaso (OTCPK:VASO) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score | Performance Potential and All-in-One Screener Examples (1) |
91 - 100 | Highest outperformance potential |
81 - 90 | Good outperformance potential |
71 - 80 | Likely to have average performance |
51 - 70 | Poor future performance potential |
0 - 50 | Worst future performance potential, or not enough data |
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Thank you for viewing the detailed overview of Vaso's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Jun Ma | director | C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590 |
Leon Dembo | director | 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803 |
Janey Moen | director | 137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803 |
Edgar Rios | director | 1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102 |
Michael Beecher | officer: Chief Financial Officer | C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716 |
Joshua Markowitz | director | 3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648 |
Jonathan P Newton | officer: Vice Pres Finance & Controller | 152 RICHMOND AVENUE, AMITYVILLE NY 11701 |
Peter C Castle | director | C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634 |
David H Lieberman | director | 3061 INDUSTRY DR, LANCASTER PA 17603 |
Behnam Movaseghi | director | C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101 |
Nelson Randall Hill | officer: Senior Vice President | 3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159 |
William Edward Dempsey | director | 52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4 |
David Tarachand Singh | officer: Chief Financial Officer | C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590 |
Joseph Giacalone | director | |
Derek Enlander | director | 88C UNION AVENUE, CENTER MORICHES NY 11934 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 10-29-2021
By ACCESSWIRE AccessWire • 04-12-2019
By ACCESSWIRE ACCESSWIRE • 06-04-2021
By ACCESSWIRE ACCESSWIRE • 08-13-2021
By ACCESSWIRE ACCESSWIRE • 11-14-2022
By ACCESSWIRE ACCESSWIRE • 11-13-2020
By ACCESSWIRE AccessWire • 04-12-2019
By [email protected] [email protected] • 08-14-2019
By ACCESSWIRE ACCESSWIRE • 08-14-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.